SER150 (formerly EV 077) is an inhibitor of thromboxane synthase and an antagonist of the thromboxane prostanoid receptor. It was developed for diabetic nephropathy.[1][2][3]
References[edit]
- ^ Kim, Yoon Kook; Ning, Xinyuan; Munir, Kashif M.; Davis, Stephen N. (2 October 2022). "Emerging drugs for the treatment of diabetic nephropathy". Expert Opinion on Emerging Drugs. 27 (4): 417–430. doi:10.1080/14728214.2022.2155632.
- ^ McFarlane, Samy I. (2020). Kidney Disease in Diabetes. Bentham Science Publishers. p. 101. ISBN 978-981-14-2199-0.
- ^ Tan, Seng Kiong; Cooper, Mark E. (28 October 2023). "Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?". Expert Opinion on Emerging Drugs. 28 (4): 217–226. doi:10.1080/14728214.2023.2277762.